Mezzion Pharma Co.,Ltd.
KOSDAQTotal Valuation
Mezzion Pharma Co.,Ltd. carries a market capitalization of 1.65T, placing it among publicly traded companies globally. Its enterprise value stands at 2.61T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.65T |
| Enterprise Value | 2.61T |
Valuation Ratios
The price-to-sales ratio is 327.61, and the price-to-book ratio stands at -15.52.
| PE Ratio | N/A |
| PS Ratio | 327.61 |
| PB Ratio | -15.52 |
| P/TBV Ratio | -62.22 |
| P/FCF Ratio | -371.32 |
| P/OCF Ratio | -137.80 |
Enterprise Valuation
| EV / Sales | 326.98 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 136.49 |
Financial Position
Mezzion Pharma Co.,Ltd. maintains a current ratio of 0.47, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 80.08, indicating elevated leverage, while an interest coverage ratio of -6.61 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.47 |
| Quick Ratio | 0.21 |
| Debt / Equity | 80.08 |
| Debt / EBITDA | -0.89 |
| Interest Coverage | -6.61 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -43.51 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.22 |
Taxes
| Income Tax | -3.91B |
| Effective Tax Rate | N/A |
Stock Price Statistics
Mezzion Pharma Co.,Ltd.'s stock has gained approximately 48.08743% over the past 52 weeks. The 50-day moving average sits at 70,328.00, while the 200-day moving average is 87,655.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 48.08743% |
| 50-Day Moving Average | 70,328.00 |
| 200-Day Moving Average | 87,655.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Mezzion Pharma Co.,Ltd. generated 7.97B in revenue and converted that into -36.93B in net income, yielding earnings per share of -1,226.90. EBITDA reached -13.93B, while operating income came in at -13.93B.
| Revenue | 7.97B |
| Gross Profit | 1.45B |
| Operating Income | -13.93B |
| Pretax Income | -40.84B |
| Net Income | -36.93B |
| EBITDA | -13.93B |
| EBIT | -13.93B |
| Earnings Per Share (EPS) | -1,226.90 |
Balance Sheet
Mezzion Pharma Co.,Ltd. holds 17.42B in cash and equivalents against 12.42B in total debt, resulting in a net debt position of -6.86B. Total book value stands at -168.26B, with working capital of -43.95B providing operational flexibility.
| Cash & Cash Equivalents | 17.42B |
| Total Debt | 12.42B |
| Net Debt | -6.86B |
| Equity (Book Value) | -168.26B |
| Book Value Per Share | -5,579.45 |
| Working Capital | -43.95B |
Cash Flow
Mezzion Pharma Co.,Ltd. produced -18.95B in operating cash flow over the past twelve months. After subtracting -11.93B in capital expenditures, free cash flow totaled -30.89B - equivalent to -1,024.12 per share.
| Operating Cash Flow | -18.95B |
| Capital Expenditures | -11.93B |
| Free Cash Flow | -30.89B |
| FCF Per Share | -1,024.12 |
Margins
Mezzion Pharma Co.,Ltd. operates with a gross margin of 18.21, reflecting its pricing power and cost economics. The operating margin of -174.68 and net profit margin of -463.23 provide insight into operational efficiency.
| Gross Margin | 18.21 |
| Operating Margin | -174.68 |
| Pretax Margin | -512.26 |
| Profit Margin | -463.23 |
| EBITDA Margin | -174.68 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1.03 |
| FCF Yield | -0.27 |
Stock Splits
Mezzion Pharma Co.,Ltd.'s most recent stock split took place on April 5, 2022 with a 1:3 split ratio.
| Last Split Date | 4/5/2022 |
| Split Ratio | 1:3 |
Scores
Mezzion Pharma Co.,Ltd. posts an Altman Z-Score of 10.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.40 |